Genmab — November 2023
-
ASH23 438 Subcutaneous Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma from EPCORE NHL-5 https://ash.confex.com/ash/2023/webprogram/Paper180089.html
-
ASH23 1655 Epcoritamab SC Monotherapy Leads to Deep and Durable Responses in Patients with Relapsed or Refractory Follicular Lymphoma: First Data Disclosure from the Epcore NHL-1 Follicular Lymphoma Dose-Expansion Cohort https://ash.confex.com/ash/2023/webprogram/Paper179887.html
-
"Of the 11 patients treated, 7 received ≥1 cycle of GEN3014, and among them, the best overall responses were 1 complete response, 2 very good partial responses, 2 partial responses, 1 minimal response, and 1 stable disease."
-
WTF...JV er genopstået:-D
-
ASH23 4757 GEN3014 (HexaBodyÂ
-CD38) in Anti-CD38 Mab–Naive Patients with Relapsed/Refractory Multiple Myeloma: Preliminary Results from a Dose‑Expansion Cohort of a Phase 1/2 Trial https://ash.confex.com/ash/2023/webprogram/Paper179504.html
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind